Claritin patent extension
Senate Health Committee Chairman Jeffords (R-Vt.) allows investigation of "pipeline drug" regulatory review delays to move forward at the General Accounting Office. GAO is in the process of reviewing whether FDA held up review of certain drugs, including Schering-Plough's Claritin, resulting in the loss of patent exclusivity time as the sponsors have argued. The report was requested by Sen. Leahy (D-Vt.) and other Democrats to examine whether the delays were caused by the sponsors themselves. GAO could not access FDA approval records without the authority of a committee chairman with jurisdiction (1"The Pink Sheet" Nov. 15, 1999, p. 10)
You may also be interested in...
Vice President Gore is promising to address the potential for the FDA citizen petition process to be used to delay generic drug approvals if he is elected President.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials